IN2013MU02576A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02576A
IN2013MU02576A IN2576MU2013A IN2013MU02576A IN 2013MU02576 A IN2013MU02576 A IN 2013MU02576A IN 2576MU2013 A IN2576MU2013 A IN 2576MU2013A IN 2013MU02576 A IN2013MU02576 A IN 2013MU02576A
Authority
IN
India
Prior art keywords
carbidopa
levodopa
relates
pharmaceutical compositions
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Sushrut Krishnaji Kulkarni
Pavak Rajnikant Mehta
Sameer Sagar Kochar
Krishnakumar Vinubhai Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2576MU2013 priority Critical patent/IN2013MU02576A/en
Priority to US14/450,475 priority patent/US20150037405A1/en
Publication of IN2013MU02576A publication Critical patent/IN2013MU02576A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IN2576MU2013 2013-08-05 2013-08-05 IN2013MU02576A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2576MU2013 IN2013MU02576A (ko) 2013-08-05 2013-08-05
US14/450,475 US20150037405A1 (en) 2013-08-05 2014-08-04 Pharmaceutical compositions of levodopa and carbidopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2576MU2013 IN2013MU02576A (ko) 2013-08-05 2013-08-05

Publications (1)

Publication Number Publication Date
IN2013MU02576A true IN2013MU02576A (ko) 2015-06-12

Family

ID=54199321

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2576MU2013 IN2013MU02576A (ko) 2013-08-05 2013-08-05

Country Status (2)

Country Link
US (1) US20150037405A1 (ko)
IN (1) IN2013MU02576A (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107139C (en) * 2018-09-21 2023-01-03 Kashiv Biosciences, Llc Extended release compositions comprising trihexyphenidyl
WO2022155507A1 (en) * 2021-01-15 2022-07-21 Jubilant Pharma Holdings Inc. Transmucosal dosage forms of brexanolone
CN118141773A (zh) * 2022-12-05 2024-06-07 上海汉都医药科技有限公司 延迟定时释放的药物组合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone

Also Published As

Publication number Publication date
US20150037405A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
CR20140327A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
CL2015001358A1 (es) Potenciadores del cftr deuterados
DOP2015000156A (es) Derivados de exendina-4 funcionalizada
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
GB201209613D0 (en) New compounds
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
CL2015002897A1 (es) Inhibidores de bace1
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
IN2013MU02576A (ko)
MX2017007027A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson.
MX369778B (es) Potenciadores de solubilidad del agua a base de glucogeno.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
GB2527233A (en) Composition comprising hydrocortisone
EP2968222A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON
PH12017501979A1 (en) Pharmaceutical compound
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
IN2013MU02575A (ko)